Getting tested for diseases is becoming expensive day by day. Keeping this in mind, an Indian company has prepared such a device, which will be able to check many diseases from diabetes to thyroid. Read this news…
Image credit source: Getty
India is called the pharmacy of the world. Indian pharmaceutical companies constantly bring something new so that cheap treatment can be available to the people. Even during the Corona pandemic, India provided two cheap Covid vaccines to the world. Now an Indian company has developed such a device which can check for many infectious and stomach diseases ranging from diabetes, thyroid, fertility.
Indian Pharmaceutical Company Cipla launched its diagnostic device on Wednesday Chippoint has been launched. This same device of the company is capable of testing many diseases.
Report will come in 3 to 15 minutes
Cipla says that people will be comfortable with Sippoint. The first is that due to having many types of tests from the same machine, people will get the correct test results at a low cost. At the same time, due to its easy process and user-friendly interface, it is easy to use it from village to mobile van and remote areas.
Not only this, this device will also help health workers. With the help of this device, the test results of the disease will be available in 3 to 15 minutes.
There will be alerts for these diseases
The company says that it is a point of care testing device. It checks for infectious diseases as well as thyroid function. Apart from this, cardiac markers, inflammation, metabolic markers and coagulation markers etc. are also examined.
Due to the cheapness of the investigation of these diseases, it will help the patients to take the right decision in time. At the same time, people will also be able to keep themselves alert regarding these diseases.
Europe has got recognition
Cipla says that its device has been approved by the European In-Vitro Diagnostic Device Directive. It has been considered a reliable device for testing.
The company’s CEO (One India Business) Achin Gupta says that this will help in filling many gaps present in the diagnostic ecosystem. This will also benefit the patients at a larger level which further strengthens our vision.
: Language Inputs
